C
CTI Biopharma Corp
F:CEPS
CTI Biopharma Corp
F:CEPS
Price:
28
EUR
Market Closed
Market Cap:
€3.7B
Relative Value
There is not enough data to reliably calculate the relative value of CEPS.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CEPS
Relative Value
Base Case
Not Available
Multiples Across Competitors
CEPS Competitors Multiples
CTI Biopharma Corp Competitors
CTI Biopharma Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
CTI Biopharma Corp
F:CEPS
|
3.7B EUR | 57.5 | -62.9 | -84.3 | -80.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
390.9B USD | 6.5 | 166 | 16.1 | 22.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.7B USD | 5.3 | 25.4 | 14.6 | 14.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
192.8B USD | 6.6 | 23.8 | 16.2 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.6B USD | 9.9 | 31.7 | 23.3 | 24.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.8B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
78B AUD | 3.5 | 18.1 | 12.3 | 15.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR | 14.2 | 33.4 | 56.9 | 58.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
